# EDGAR Filing Document

**Accession Number:** 0001876431
**File Stem:** 0001193125-23-010682
**Filing Date:** 2023-1
**Character Count:** 8660
**Document Hash:** 1930f0cd62db438bf366eff077011d68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-010682.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001193125-23-010682

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230119

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prenetics Global Ltd
- **CENTRAL INDEX KEY:** 0001876431
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41401
- **FILM NUMBER:** 23536027

**BUSINESS ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000
- **BUSINESS PHONE:** (852) 2210-7188

**MAIL ADDRESS:**
- **STREET 1:** 7/F, K11 ATELIER, 728 KING'S ROAD
- **CITY:** QUARRY BAY
- **STATE:** K3
- **ZIP:** 000000

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**Form 6-K** 

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE** 

**13a-16 OR 15d-16 UNDER** 

**THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of January 2023** 

**Commission File Number 001-41401** 

------

## Prenetics Global Limited

------

**Unit 701-706, K11 Atelier King's Road** 

**728 King's Road, Quarry Bay** 

**Hong Kong** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**Appointment of Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA** 

On January 19, 2023, Dr. Bayju Thakar was appointed as Chief Executive Officer of Prenetics EMEA Limited ("Prenetics EMEA"), a wholly owned subsidiary of Prenetics Global Limited (the "Company").

The Company has filed as an exhibit to this Form 6-K a press release dated January 19, 2023 announcing the appointment.

<u>Exhibit Index</u> 

Exhibit 99.1—[Press Release](d452117dex991.htm)

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Prenetics Global Limited** | **Prenetics Global Limited** |
|  | By: | /s/ Stephen Lo |
|  | Name: | Stephen Lo |
|  | Title: | Chief Financial Officer |
|  Date: January 19, 2023 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g452117g0119144539284.jpg)

**Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA** 

LONDON AND HONG KONG, January 19, 2023 – Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commitment to the EMEA market. To be effective immediately, Dr. Bayju Thakar is appointed as CEO and shall join the board of directors for Prenetics EMEA Limited ("Prenetics EMEA"), a wholly owned subsidiary of Prenetics Global Limited.

"Prenetics has strong ambitions in the UK and EMEA markets. They are highly complex healthcare markets, which require very specific domain expertise and networks to thrive. Bayju understands the healthcare system dynamics incredibly well and is the ideal leader to significantly grow our EMEA business, creating value for all stakeholders. I am delighted to welcome Bayju Thakar as CEO of Prenetics EMEA. Bayju's vast digital health, medical, and operating experience as co-founder and ex-CEO of Doctor Care Anywhere, UK's largest telehealth primary care business with more than 2 million lives, will help Prenetics Global build a leading modern health ecosystem in EMEA and globally", said Danny Yeung, Chief Executive Officer of Prenetics Global Limited.

Dr. Bayju Thakar, Chief Executive Officer, EMEA said "I am honored to take on the EMEA CEO role and lead Prenetics forward at this important inflection point. I look forward in partnering with Danny to build upon our strong foundation and further position Prenetics as a leader in healthcare. The expertise of our team and Prenetics' strong balance sheet will enable us to pursue both organic and inorganic growth across a number of major healthcare opportunities, including primary and secondary care clinical services, IVF / fertility, and personalized cancer diagnostics.

**Dr. Bayju Thakar Biography** 

Dr. Thakar has more than 20 years of healthcare and digital health, M&A, strategic partnerships and board experience. Most recently, Dr. Thakar served as Co-Founder and former CEO of Doctor Care Anywhere Group PLC, UK's largest telehealth primary care business with more than 2 million lives under coverage. Dr. Thakar trained as a medical doctor at King's College, London, and then practised in both General and Emergency medicine before a move to consulting at McKinsey & Company.

**About Prenetics** 

Founded in 2014, Prenetics is a major global diagnostic and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Consumer Health, Clinical Care and Medical & Cancer Genomics — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across nine locations, including The United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening and provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. Prenetics is listed on NASDAQ with the ticker PRE. To learn more about Prenetics, visit www.prenetics.com.

**Investor Relations Contact:** 

investors@prenetics.com

---

| | | |
|:---|:---|:---|
|  **ICR Westwicke:** |  |  |
|  Caroline Corner | +415 202 5678 | Email: caroline.corner@westwicke.com |
|  **Media contact:** |  |  |
|  **Strategic Public Relations Group** |  |  |
|  Corinne Ho | +852 2114 4911 | Email: corinne.ho@sprg.com.hk |

---

------

![LOGO](g452117g0119144539284.jpg)

**Forward-Looking Statements** 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms of other similar expressions. Forward-looking statements are based on Prenetics' expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to: Prenetics' ability to execute its strategies, manage growth and maintain its corporate culture as it grows; the regulatory environment and changes in laws, regulations, or policies in which Prenetics operates; Prenetics' ability to successfully compete in highly competitive industries and markets; Prenetics' ability to continue to adjust its offerings to meet market demand; Prenetics ability to attract customers to choose its products and services and grow its ecosystem; political instability in the jurisdictions in which Prenetics operates; and the overall economic environment and general market and economic conditions in the jurisdictions in which Prenetics operates. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties included in Prenetics' filings with the U.S. Securities and Exchange Commission (the "SEC") from time to time.

Forward-looking statements speak only as of the date they are made. Prenetics does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required under applicable law.